A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-03-10) →
What happened
HLB Pharmaceutical reported consolidated results for FY2025: revenue of US$142M (+50% year on year), operating profit of US$728K (−28.4% year on year) and net income of US$1.77M (+26.9% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$142M |
|---|---|
| Revenue vs a year earlier | +50% |
| Operating profit | US$728K |
| Net income | US$1.77M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-02, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260202901463 → open original filing |
Versions of this filing
- 2026-02-02Original (this page)
- 2026-03-10Amendment 1
Source: DART. Information only, not investment advice.